[go: up one dir, main page]

MX2018011249A - Composiciones topicas no acuosas que comprenden una salicilanilida halogenada. - Google Patents

Composiciones topicas no acuosas que comprenden una salicilanilida halogenada.

Info

Publication number
MX2018011249A
MX2018011249A MX2018011249A MX2018011249A MX2018011249A MX 2018011249 A MX2018011249 A MX 2018011249A MX 2018011249 A MX2018011249 A MX 2018011249A MX 2018011249 A MX2018011249 A MX 2018011249A MX 2018011249 A MX2018011249 A MX 2018011249A
Authority
MX
Mexico
Prior art keywords
halogenated
salicilanilide
compositions including
aqueous compositions
topical
Prior art date
Application number
MX2018011249A
Other languages
English (en)
Other versions
MX383448B (es
Inventor
Li Ping
otto alexander sommer Morten
Hasling Frandsen Camilla
Mørck Nielsen Hanne
Alexandra Priemel Petra
Rades Thomas
Original Assignee
Antibiotx As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antibiotx As filed Critical Antibiotx As
Publication of MX2018011249A publication Critical patent/MX2018011249A/es
Publication of MX383448B publication Critical patent/MX383448B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones tópicas no acuosas que comprenden una salicilanilida halogenada y al uso de tales composiciones en el tratamiento tópico o prevención de enfermedades e infecciones, particularmente afecciones causadas por bacterias Grampositivas, por ejemplo, el tratamiento tópico o prevención de infecciones cutáneas como el acné, la dermatitis atópica y el impétigo; también se describen métodos para preparar la composición de gel.
MX2018011249A 2016-03-16 2017-03-15 Composiciones tópicas no acuosas que comprenden una salicilanilida halogenada. MX383448B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1604484.4A GB201604484D0 (en) 2016-03-16 2016-03-16 Topical antibacterial compositions
PCT/EP2017/056083 WO2017157997A1 (en) 2016-03-16 2017-03-15 Non-aqueous topical compositions comprising a halogenated salicylanilide

Publications (2)

Publication Number Publication Date
MX2018011249A true MX2018011249A (es) 2019-09-16
MX383448B MX383448B (es) 2025-03-14

Family

ID=55952410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011249A MX383448B (es) 2016-03-16 2017-03-15 Composiciones tópicas no acuosas que comprenden una salicilanilida halogenada.

Country Status (13)

Country Link
US (1) US12036312B2 (es)
EP (1) EP3429691B1 (es)
JP (1) JP2019508463A (es)
KR (1) KR20180123542A (es)
CN (1) CN108883309B (es)
AU (1) AU2017234199A1 (es)
BR (1) BR112018068593A2 (es)
CA (1) CA3013673A1 (es)
DK (1) DK3429691T3 (es)
ES (1) ES2848199T3 (es)
GB (1) GB201604484D0 (es)
MX (1) MX383448B (es)
WO (1) WO2017157997A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3010511T3 (en) 2014-09-12 2018-03-05 Antibiotx As ANTIBACTERIAL USE OF HALOGENERED SALICYLANILIDES
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
GB201713653D0 (en) * 2017-08-24 2017-10-11 Antibiotx As Dosage regimen
GB201813876D0 (en) * 2018-08-24 2018-10-10 Antibiotx As Treatment
WO2020089467A1 (en) * 2018-11-02 2020-05-07 UNION therapeutics A/S Dosage regimen
BR112021008417A2 (pt) * 2018-11-02 2021-09-14 UNION therapeutics A/S Salicilanilidas halogenadas para tratar os sintomas de dermatite
CN109331025A (zh) * 2018-11-22 2019-02-15 华中农业大学 羟氯扎胺在制备抗猪链球菌的药物中的应用
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
EP4025562A4 (en) * 2019-09-06 2024-01-17 Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET) PHARMACEUTICAL COMPOSITION FOR THE TOPICAL TREATMENT OF WOUNDS
JP2023520229A (ja) 2020-04-01 2023-05-16 ユニオン・セラピューティクス・アー／エス 製剤
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
EP4125804A1 (en) 2020-04-01 2023-02-08 UNION therapeutics A/S Treatment
CN111743860B (zh) * 2020-06-30 2022-04-05 成都中牧生物药业有限公司 一种混悬液药物配方
CN111821260B (zh) * 2020-06-30 2022-04-01 成都中牧生物药业有限公司 用于混悬液药物的生产方法
WO2022169373A1 (en) * 2021-02-04 2022-08-11 Alan Moana Alexander Niclosamide compositions having improved bioavailability
GB202102488D0 (en) 2021-02-22 2021-04-07 Union Therapeutics As Treatment
CN113908121B (zh) * 2021-10-13 2023-03-28 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种氯硝柳胺注射液及其制备和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731386A (en) 1951-09-06 1956-01-17 Wallace & Tiernan Company Inc Antifungal composition
US3152039A (en) 1960-11-23 1964-10-06 Dow Chemical Co Germicidal compositions
FR1340175A (fr) 1962-03-06 1963-10-18 Procter & Gamble Nouvelles compositions bactéricides
US3674850A (en) 1969-12-07 1972-07-04 Lever Brothers Ltd Substituted salicylanilides
US3914418A (en) 1971-09-02 1975-10-21 Merck & Co Inc Methods of controlling liver fluke infections
GB1421589A (en) 1972-03-07 1976-01-21 Janssen Pharmaceutica Nv Salicylanilide derivatives
DE2557615C2 (de) 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
SU597671A1 (ru) 1976-10-07 1978-03-15 Предприятие П/Я М-5400 Способ очистки 3,4,5-трибромсалициланилида
DE3584236D1 (de) 1984-12-12 1991-10-31 Euro Celtique Sa Antibakterielle creme.
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
EP0487973B1 (en) 1990-11-26 1996-03-27 Bayer Corporation Topical lotion containing Niclosamide
WO1996019220A1 (en) 1994-12-19 1996-06-27 Lauteral Limited A combination product comprising nitazoxanide and an anti-ulcer agent
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0984783A1 (en) 1997-06-11 2000-03-15 Bayer Ag Anthelmintic compositions
DE69902526T2 (de) 1998-05-18 2003-04-03 Pharmacia & Upjohn Co., Kalamazoo Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
DE19859426A1 (de) 1998-12-22 2000-07-06 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
AU2001239774A1 (en) 2000-02-18 2001-08-27 The Procter And Gamble Company Antibacterial agents and compositions, methods and systems employing same
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
RU2227025C2 (ru) 2002-05-21 2004-04-20 ЗАО "Агроветсервис" Антипаразитарный препарат широкого спектра действия
KR101054562B1 (ko) 2002-06-06 2011-08-04 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 항알레르기약
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP4446678B2 (ja) 2003-05-08 2010-04-07 株式会社ノエビア 抗菌剤
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
TW200519126A (en) 2003-09-16 2005-06-16 Fujisawa Pharmaceutical Co An antibacterial agent a against propionibacterium acnes
US7666444B2 (en) * 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
US8198326B2 (en) 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US20060222692A1 (en) 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
BRPI0611134A2 (pt) 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
JP4920206B2 (ja) * 2005-06-30 2012-04-18 ライオン株式会社 外用剤組成物及び貼付剤、並びに薬物の経皮吸収組成物
GB0525093D0 (en) * 2005-12-09 2006-01-18 Norbrook Lab Ltd Veterinary composition
US7727513B2 (en) 2005-12-15 2010-06-01 Kimberly-Clark Worldwide, Inc. Method for screening for bacterial conjunctivitis
CN101370480A (zh) 2006-02-03 2009-02-18 赢创罗姆有限责任公司 含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
WO2008006848A1 (en) 2006-07-13 2008-01-17 Galderma Research & Development Composition comprising a retinoid and benzoyl peroxide
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008092006A2 (en) 2007-01-24 2008-07-31 Cernofina, Llc Antimicrobial compositions
US20100273876A1 (en) 2007-05-31 2010-10-28 Scott Seville antibacterial formulation comprising a dialkyl sulphosuccinate and a carbanilide antibacterial agent
GB0711957D0 (en) 2007-06-21 2007-08-01 Syntopix Ltd Formulations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
PL2214643T3 (pl) 2007-11-02 2014-09-30 Acrux Dds Pty Ltd Układ transdermalnego dostarczania hormonów i steroidów
ES2324192B1 (es) 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
MX2010009891A (es) 2008-03-07 2011-03-04 Lectec Corp Parche desinfectante para las manos.
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
US20100029781A1 (en) 2008-06-04 2010-02-04 Morris Jerome A Methods for preparation of anti-acne formulation and compositions prepared thereby
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
US9050293B2 (en) 2008-07-16 2015-06-09 Juventio, Llc Small molecule solubilization system
US8846646B2 (en) 2008-10-03 2014-09-30 Winlind Skincare, Llc Topical treatment of skin infection
EP2177208A1 (en) 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Pharmaceutical topical compositions
GB2465633A (en) * 2008-12-01 2010-06-02 Syntopix Ltd Anti-acne formulation
GB2456376A (en) * 2008-12-22 2009-07-15 Syntopix Ltd Antibacterial/anti-acne formulations comprising a halogenated salicylanilide in combination with one or more anti-acne agents
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
CN102834116B (zh) * 2009-09-21 2015-09-16 杜克大学 Wnt/卷曲蛋白相关疾病的治疗
FR2961810B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Esters de metronidazole pour traiter la rosacee
JP5518595B2 (ja) 2010-06-30 2014-06-11 日本エンバイロケミカルズ株式会社 工業用防腐・防汚組成物
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
DE102010054149A1 (de) 2010-12-10 2012-06-14 Merck Patent Gmbh 2-Pyrone
CA2829791A1 (en) 2011-03-28 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sustained-release injectable formulation
US20140294957A1 (en) 2011-04-18 2014-10-02 Maxdelbruck-Centrum Fur Molekulare Medizin Niclosamide for the treatment of cancer metastasis
US9034812B2 (en) 2011-08-26 2015-05-19 Ohio University Compositions and methods for treating biofilms
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
WO2014117236A1 (pt) 2013-01-30 2014-08-07 Universidade Federal Do Rio De Janeiro - Ufrj Nanoemulsão óleo em água e seu processo de produção
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CA2902282C (en) 2013-02-27 2023-03-14 Laurie Robert BATT Transdermal formulations
WO2014200705A1 (en) 2013-06-14 2014-12-18 Stc.Unm Treatment of autophagy-related disorders
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2016036839A1 (en) 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
DK3010511T3 (en) 2014-09-12 2018-03-05 Antibiotx As ANTIBACTERIAL USE OF HALOGENERED SALICYLANILIDES
US20190328687A1 (en) 2014-11-17 2019-10-31 Victoria Link Limited Antibacterial Compounds
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2016210247A1 (en) 2015-06-24 2016-12-29 Duke University New methods of use for an anti-diarrhea agent
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
CA2955296C (en) 2016-01-21 2024-01-02 Midmark Corporation Medical examination table with retractable moving wheels
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
US10940163B2 (en) 2017-02-02 2021-03-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
US11709169B2 (en) 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
GB201805453D0 (en) 2018-04-03 2018-05-16 Antibiotx As Novel use
GB201813876D0 (en) 2018-08-24 2018-10-10 Antibiotx As Treatment
US20210369650A1 (en) 2018-11-02 2021-12-02 UNION therapeutics A/S Treatment of inflammatory conditions
WO2020176067A1 (en) 2019-02-25 2020-09-03 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
EP4125804A1 (en) 2020-04-01 2023-02-08 UNION therapeutics A/S Treatment
JP2023520229A (ja) 2020-04-01 2023-05-16 ユニオン・セラピューティクス・アー／エス 製剤
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Also Published As

Publication number Publication date
EP3429691A1 (en) 2019-01-23
AU2017234199A1 (en) 2018-08-09
WO2017157997A1 (en) 2017-09-21
US20190151231A1 (en) 2019-05-23
BR112018068593A2 (pt) 2019-04-16
GB201604484D0 (en) 2016-04-27
KR20180123542A (ko) 2018-11-16
ES2848199T3 (es) 2021-08-05
CN108883309B (zh) 2021-08-17
EP3429691B1 (en) 2020-11-04
CN108883309A (zh) 2018-11-23
DK3429691T3 (da) 2021-02-08
CA3013673A1 (en) 2017-09-21
US12036312B2 (en) 2024-07-16
JP2019508463A (ja) 2019-03-28
MX383448B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
MX2018011249A (es) Composiciones topicas no acuosas que comprenden una salicilanilida halogenada.
MX2016009898A (es) Tratamientos para acne resistente.
CO2022000278A2 (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
AU2018333114A1 (en) New use for treatment of Clostridium difficile infections
CL2018003425A1 (es) Composiciones de cannabidiol y usos de las mismas.
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112014026058A2 (pt) composições para tratamento tópico de infecções microbianas
GT201600183A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
MX2017003251A (es) Uso antibacteriano de salicilanilidas halogenadas.
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
WO2016179440A3 (en) Antimicrobial therapy
MX391192B (es) Composiciones dispersables que comprenden fumarato de bedaquilina para uso en el tratamiento de enfermedades antibacterianas.
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX2017004998A (es) Composicion que contiene un extracto o fraccion de una planta del genero justicia.
PH12016501988A1 (en) Antibacterial compounds
MX2018005489A (es) Agente antimicrobiano que comprende xantohumol y su uso en productos alimenticios.
MX376183B (es) Composiciones para el tratamiento de rosacea.
WO2016057413A3 (en) Inhibitors of lysine gingipain
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
WO2015079469A8 (en) Daphne laureola extracts in the treatment of dermopathies